Marina P. Zazanis, President and CEO, the co-founder of Kytogenics in 1993, has since her early years with the family business always been involved in an executive business capacity. From 1956 until the present, she has been involved as shareholder and Director of Clement Pappas & Co., Inc., a privately owned family business based in Carney's Point, NJ, a manufacturer of various fruit and beverage products with current sales in the range of $400 million. In 1983, she was a co-founder of NMR of America, Inc. ("NMR") a $15 million in revenue public company engaged in developing, installing, managing and maintaining magnetic resonance imaging centers for diagnostic purposes in clinics throughout the United States. In 1987, Ms. Zazanis was elected President and CEO of this company. NMR was named the fortieth fastest growing company in the USA in 1990 according to Inc. Magazine's annual survey that year. In 1986 net revenues were $2,526,893 after which under Ms. Zazanis' leadership net revenue in 1990 was $15,676.00 and net income was $1,225,000. In 1990, NMR was named one of the top New Jersey companies by Business Journal of New Jersey and number two in the top ten companies in return on equity with a 45.9% return.

From 1991 until 1993 when she founded Kytogenics, Ms. Zazanis was President of NeoGenix, Inc., a research and development company, involved in the development of proprietary products for expanding the treatment of osteoarthritis.

At Kytogenics, she has been responsible for managing the research and development of the Chitin platform technology, the merger with Nova Chem in 1993, the recruitment of its current outstanding Management team, Board of Directors and Scientific Advisory Board and the funding to date of its operations from institutions and high net worth individuals. Ms. Zazanis has a B.A. degree in English from Hood College, Frederick MD. She is on the Board of Clement Pappas & Company, served on the Board of Directors of the Beaches, on the Alumni Board of Hood College, was a trustee of the Maliotis Foundation, and is a member of the Controlled Release Society.

Agis Kydonieus, Ph.D., Vice President, Basic Research has had an extensive and outstanding career in the biotechnical industry, both on the technical side and in the management of businesses. As a co-founder of the Controlled Release Society and formerly its President, he is considered in the profession to be among the leaders in drug delivery and is knowledgeable in the fields of transdermal, implantable, buccal and vaginal delivery, oral delivery of peptides as well as in the fields of biopolymers, resorbable and non-resorbable for medical devices, including devices for orthopedics, adhesion prevention, ophthalmics, wound care, cardiovascular applications, as well as for cosmetics and skin care.

In 1988, Dr. Kydonieus joined the Bristol-Meyers Squibb Corporation ("BMS") as Vice President, Corporate Research and Development for the Convatec Subsidiary. For the next ten years, he led the company's effort in polymer and process research, drug delivery, skin biology, analytical chemistry, clinical supply and pre-clinical testing groups.

Dr. Kydonieus leads the basic research at Kytogenics where he devotes approximately 50% of his business time. He has generated approximately 40 U.S. patents and patent applications in drug delivery, adhesives and many other applications. In addition, he has edited ten books in drug delivery, contributed various chapters in many drug delivery and controlled release publications and has authored or co-authored over 100 scientific papers and abstracts. Dr. Kydonieus has a B.S. Degree Summa Cum Laude 1959 and a Ph.D. in Chemical Engineering 1964 from the University of Florida. He is currently a member of the Controlled Release Society, Inc. 1978-Present (Co-founder, President, Vice President, Board Member, Trustee).

Samia Mankarious, Vice President, Product Development. Previously with Baxter BioScience as Director, R & D - External Collaboration, Ms. Mankarious joined Kytogenics in 2003. She was with Baxter BioScience for 19 years and was responsible for directing R & D, patent and invention records and manufacturing process improvement. She established the Formulation group, Product Stability Department, and Cellular and Molecular Biology groups within Baxter Bio Science. Ms. Mankarious has a B.S. from Cairo University and a M.S. from University of Wisconsin. She is a member of several professional organizations and has an extensive list of publications.

Gerard Wadden, VP, Finance.  Mr. Wadden spent over 20 years in accounting and finance.  He has worked in technology start-up companies in the biotech and environmental industries. He served as VP of Finance for ImmunoVaccine Technologies and the Phase Group of Companies.